In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Toray gets rights to Acologix's AC200 for hyperphosphatemia

Executive Summary

Toray Industries has licensed exclusive Japanese rights to Acologix's (developing drug candidates for osteo-renal diseases) AC200, a recombinant protein in preclinical studies for hyperphosphatemia. Acologix originally obtained the exclusive rights to AC200 under a 1999 deal with University College London.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register